Category: 69256-17-3

Accurately Modeling the Conformational Preferences of Nucleosides was written by Burai Patrascu, Mihai; Malek-Adamian, Elise; Damha, Masad J.; Moitessier, Nicolas. And the article was included in Journal of the American Chemical Society on October 4,2017.Safety of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

Sugar puckering of nucleosides impacts nucleic acid structures; hence their biol. function. Similarly, nucleoside-based therapeutics may adopt different conformations affecting their binding affinity, DNA incorporation, and excision rates. As a result, significant efforts have been made to develop nucleoside analogs adopting specific conformations to improve bioactivity and pharmacokinetic profiles of the corresponding nucleoside-containing drugs. Understanding and ultimately predicting these conformational preferences would significantly help in the design of more effective structures. The authors report herein a computational study based on hybrid QM/MM umbrella sampling simulations that allow the accurate prediction of the sugar conformational preferences of chem. modified nucleosides in solution Moreover, the authors pair these simulations with natural bond orbital (NBO) anal. to gain key insights into the role of substituents in the conformational preferences of these nucleosides. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Safety of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. Drugs having the pyrimidine motif have manifested to exhibit gratifying biological activity like anticancer, antiviral, anti-inflammatory, antibacterial, and antihypertensive activities.Safety of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Rapid Enantiomeric Quantification of an Antiviral Nucleoside Agent (D,L-FMAU, 2′-Fluoro-5-methyl-β,D,L-arabinofurano- syluracil) by Mass Spectrometry was written by Tao, W. Andy; Wu, Lianming; Cooks, R. Graham; Wang, Feng; Begley, John A.; Lampert, Bernhard. And the article was included in Journal of Medicinal Chemistry on October 25,2001.HPLC of Formula: 69256-17-3 The following contents are mentioned in the article:

A novel mass spectrometric method was applied to rapid, accurate (<1%) quantification of chiral Clevudine (L-FMAU, 2'-fluoro-5-methyl-β,L-arabinofuranosyluracil), a potent antiviral nucleoside agent against hepatitis B virus. Transition metal bound complex ions containing the chiral drug are generated by electrospray ionization mass spectrometry and subjected to collision-induced dissociation The ratio of the two competitive dissociation rates is related to the enantiomeric composition of the drug mixture, allowing the determination of enantiomeric contamination in the drug. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3HPLC of Formula: 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. Therapy for fungal infections is based mainly on four classes of antifungals: azoles, echinocandins, polyenes, and pyrimidine analogs.HPLC of Formula: 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Pharmacological disposition and metabolic fate of 2′-fluoro-5-iodo-1-β-D-arabinofuranosylcytosine in mice and rats was written by Chou, Ting-Chao; Feinberg, Aaron; Grant, Alan J.; Vidal, Pedro; Reichman, Uri; Watanabe, Kyoichi A.; Fox, Jack J.; Philips, Frederick S.. And the article was included in Cancer Research on September 30,1981.Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

2′-Fluoro-5-iodo-1-β-D-arabinofuranosylcytosine-HCl (FIAC)(I) [69123-90-6] was synthesized and labeled with 14C in the 2 position for the study of pharmacol. disposition and metabolic fate. FIAC is deaminated by cytosine nucleoside deaminase [9025-06-3] at a rate comparable to that of 1-β-D-arabinofuranosylcytosine. The deaminated product, 2′-fluoro-5-iodo-1-β-D-arabinofuranosyluracil (FIAU) [69123-98-4] is, like FIAC, an active antiviral agent. After i.v. injection of [2-14C]-FIAC in mice, most of the radioactivity in plasma appears as FIAU. In i.v.-injected rats which lack cytosine nucleoside deaminase, plasma radioactivity is largely present in unchanged FIAC. If mice are pretreated with tetrahydrouridine, an inhibitor of the nucleoside deaminase, plasma radioactivity is mostly FIAC. The radioactivity of [2-14C]-FIAC injected i.v. is excreted in urine, at 63 to 93% of the dose in mice and >90% of the dose in rats within 0 to 24 h. Most of the radioactivity in urine of rats and in mice pretreated with tetrahydrouidine is present as unchanged FIAC; in control mice, most of the radioactivity is found as FIAU. Chromatog. anal. of urine from control mice receiving labeled FIAC has revealed that radioactivity is present in the following nucleosides: FIAC (14.5); FIAU (73); 2′-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU) [69256-17-3] (5.4); and 2′-fluoro-1-β-D-arabinofuranosyluracil [69123-94-0] (2.3%). These metabolites are also present in acid-soluble fractions of mouse blood, small intestine, and liver. Like FIAC and FIAU, FMAU is a potent antiherpetic agent. Only ∼4.3% of the radioactivity of injected [2-14C]-FIAC appears in mouse respiratory CO2; degradation to CO2 can be blocked by tetrahydrouridine. Less than 2% of the total radioactivity is excreted in bile in rats. Small amounts of radioactivity are also recovered in feces, mostly in deaminated products. FIAC and FIAU, with a 2′-F substituent in the arabino configuration, are less susceptible to metabolic glycosyl cleavage than is 5-iodo-2′-deoxyuridine. The radioactivity of [2-14C]-FIAC is incorporated into DNA fractions of highly proliferating organs such as intestine, spleen, and thymus, although preliminary results indicate that the substances incorporated are arabinofuranosyl nucleoside metabolites of FIAC. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. We all know its importance to life – pyrimidine and purine bases are included in the structure of DNA and RNA.Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Different modes of transport for 3H-thymidine, 3H-FLT and 3H-FMAU in proliferating and nonproliferating human tumor cells was written by Plotnik, David A.; Emerick, Lindsay E.; Krohn, Kenneth A.; Unadkat, Jashvant D.; Schwartz, Jeffrey L.. And the article was included in Journal of Nuclear Medicine on September 30,2010.Formula: C10H13FN2O5 The following contents are mentioned in the article:

The basis for the use of nucleoside tracers in PET is that activity of the cell-growth-dependent enzyme thymidine kinase 1 is the rate-limiting factor driving tracer retention in tumors. Recent publications suggest that nucleoside transporters might influence uptake and thereby affect the tracer signal in vivo. Understanding transport mechanisms for different nucleoside PET tracers is important for evaluating clin. results. This study examined the relative role of different nucleoside transport mechanisms in uptake and retention of [methyl-3H]-3′-deoxy-3′-fluorothymidine (3H-FLT), [methyl-3H]-thymidine (3H-thymidine), and 3H-1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-methyluracil (3H-FMAU). Methods: Transport of 3H-FLT, 3H-thymidine, and 3H-FMAU was examined in a single human adenocarcinoma cell line, A549, under both nongrowth and exponential-growth conditions. Results: 3H-Thymidine transport was dominated by human equilibrative nucleoside transporter 1 (hENT1) under both growth conditions. 3H-FLT was also transported by hENT1, but passive diffusion dominated its transport. 3H-FMAU transport was dominated by human equilibrative nucleoside transporter 2. Cell membrane levels of hENT1 increased in cells under exponential growth, and this increase was associated with a more rapid rate of uptake for both 3H-thymidine and 3H-FLT. 3H-FMAU transport was not affected by changes in growth conditions. All 3 tracers concentrated in the plateau phase, nonproliferating cells at levels many-fold greater than their concentration in buffer, in part because of low levels of nucleoside metabolism, which inhibited tracer efflux. Conclusion: Transport mechanisms are not the same for 3H-thymidine, 3H-FLT, and 3H-FMAU. Levels of hENT1, an important transporter of 3H-FLT and 3H-thymidine, increase as proliferating cells enter the cell cycle. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Formula: C10H13FN2O5).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. We all know its importance to life – pyrimidine and purine bases are included in the structure of DNA and RNA.Formula: C10H13FN2O5

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

2′-Deoxy-2′-fluoro-β-D-arabinonucleosides and oligonucleotides (2’F-ANA): synthesis and physicochemical studies was written by Wilds, Christopher J.; Damha, Masad J.. And the article was included in Nucleic Acids Research on September 15,2000.Formula: C10H13FN2O5 The following contents are mentioned in the article:

Recently, hybrids of RNA and D-arabinonucleic acids (ANA) as well as the 2′-deoxy-2′-fluoro-D-arabinonucleic acid analog (2’F-ANA) were shown to be substrates of RNase H. This enzyme is believed to be involved in the primary mechanism by which antisense oligonucleotides cause a reduction in target RNA levels in vivo. To gain a better understanding of the properties of arabinose based oligonucleotides, we have prepared a series of 2’F-ANA sequences of homopolymeric (A and T) and mixed base composition (A, T, G and C). UV thermal melting and circular dichroic (CD) studies were used to ascertain the thermodn. stability and helical conformation of 2’F-ANA/RNA and 2’F-ANA/DNA hybrids. It is shown that 2’F-ANA has enhanced RNA affinity relative to that of DNA and phosphorothioate DNA. The 2′-fluoroarabino modification showed favorable pairing to single-stranded DNA also. This is in sharp contrast to ANA, which forms weak ANA/DNA hybrids at best. According to the measured thermodn. parameters for duplex formation, the increased stability of hybrids formed by 2’F-ANA (e.g., 2’F-ANA/RNA) appears to originate from conformational pre-organization of the fluorinated sugars and a favorable enthalpy of hybridization. In addition, NMR spectroscopy revealed a five-bond coupling between the 2’F and the base protons (H6/H8) of 2′-deoxy-2′-fluoro-β-D-arabinonucleosides. This observation is suggesting of a through-space interaction between 2’F and H6/H8 atoms. CD experiments indicate that 2’F-ANA/RNA hybrids adopt an ‘A-like’ structure and show more resemblance to DNA/RNA hybrids than to the pure RNA/RNA duplex. This feature is believed to be an important factor in the mechanism that allows RNase H to discriminate between 2’F-ANA/RNA (or DNA/RNA) and RNA/RNA duplexes. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Formula: C10H13FN2O5).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. Drugs having the pyrimidine motif have manifested to exhibit gratifying biological activity like anticancer, antiviral, anti-inflammatory, antibacterial, and antihypertensive activities.Formula: C10H13FN2O5

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Mechanisms of substrate selectivity for Bacillus anthracis thymidylate kinase was written by Carnrot, Cecilia; Wang, Liya; Topalis, Dimitri; Eriksson, Staffan. And the article was included in Protein Science on September 30,2008.Safety of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

Bacillus anthracis is well known in connection with biol. warfare. The search for new drug targets and antibiotics is highly motivated because of upcoming multiresistant strains. Thymidylate kinase is an ideal target since this enzyme is at the junction of the de novo and salvage synthesis of dTTP, an essential precursor for DNA synthesis. Here the expression and characterization of thymidylate kinase from B. anthracis (Ba-TMPK) is presented. The enzyme phosphorylated deoxythymidine-5′-monophosphate (dTMP) efficiently with Km and Vmax values of 33 μM and 48 μmol mg-1 min-1, resp. The efficiency of deoxyuridine-5′-monophosphate phosphorylation was ∼10% of that of dTMP. Several dTMP analogs were tested, and D-FMAUMP (2′-fluoroarabinosyl-5-methyldeoxyuridine-5′-monophosphate) was selectively phosphorylated with an efficiency of 172% of that of D-dTMP, but L-FMAUMP was a poor substrate as were 5-fluorodeoxyuridine-5′-monophosphate (5FdUMP) and 2′,3′-dideoxy-2′,3′-didehydrothymidine-5′-monophosphate (d4TMP). No activity could be detected with 3′-azidothymidine-5′-monophosphate (AZTMP). The corresponding nucleosides known as efficient anticancer and antiviral compounds were also tested, and D-FMAU was a strong inhibitor with an IC50 value of 10 μM, while other nucleosides-L-FMAU, dThd, 5-FdUrd, d4T, and AZT, and 2′-arabinosylthymidine-were poor inhibitors. A structure model was built for Ba-TMPK based on the Staphylococcus aureus TMPK structure. Docking with various substrates suggested mechanisms explaining the differences in substrate selectivity of the human and the bacterial TMPKs. These results may serve as a start point for development of new antibacterial agents. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Safety of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. A Cu-catalyzed and 4-HO-TEMPO-mediated [3 + 3] annulation of commercially available amidines with saturated ketones enables an efficient and facile synthesis of structurally important pyrimidines via a cascade reaction of oxidative dehydrogenation/annulation/oxidative aromatization.Safety of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Synthesis and biological effects of 2′-fluoro-5-ethyl-1-β-D-arabinofuranosyluracil was written by Chou, Ting Chao; Kong, Xiang Bin; Fanucchi, Michael P.; Cheng, Yung Chi; Takahashi, Kiyobumi; Watanabe, Kyoichi A.; Fox, Jack J.. And the article was included in Antimicrobial Agents and Chemotherapy on September 30,1987.Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

2′-Fluoro-5-ethyl-1-β-D-arabinofuranosyluracil (I) was synthesized, and its biol. activities were compared with those of 5′-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (II). Earlier studies indicated that both compounds have potent anti-herpes simplex virus activity, with a ED50 of <0.25 μM. The cell growth inhibitory activity of I (ED50, 200-2,060 μM) was about 100-fold less than that of II. With an ED50 ranging from 630 to 3,700 μM, I only weakly inhibited thymidine incorporation into DNA, as compared with II with an ED50 of 9-28 μM. Following exposure to [2-14C]-I (100 μM), 0.48 pmol/106 cells per h was incorporated into the DNA of herpes simplex virus type 1-infected Vero cells, whereas no detectable incorporation was found in uninfected Vero cells or L1210 cells. The Ki of I for thymidine kinase purified from human leukemic cells was >150 μM. For herpes simplex virus type 1- and 2-encoded thymidine kinases, the Kis were 0.6 and 0.74 μM, resp. Both I and II were relatively nontoxic for mice, with a LD50 of >800 mg/kg/day (4 i.p. doses). However, the LD of I for dogs was 100 mg/kg/day (10 i.v. doses), a dose which is 40-80-fold greater than the toxic dose of II. These results suggest that I is a worthy candidate for further development as an antiherpetic agent. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidines are isomeric with two other forms of diazines: pyridazine, with the nitrogen atoms in the 1 and 2 positions; and pyrazine, with the nitrogen atoms in the 1 and 4 positions. As nucleotides in DNA and RNA, pyrimidine nucleotide derivatives have a wide range of biological applications. For example, pyrimidine derivatives are useful in DNA repair studies involving cancer and epigenetics.Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Treatment of primary acute genital herpes in guinea pigs by intraperitoneal administration of fluoropyrimidines was written by Mayo, Donald R.; Hsiung, G. D.. And the article was included in Antimicrobial Agents and Chemotherapy on September 30,1984.Recommanded Product: 69256-17-3 The following contents are mentioned in the article:

[1-(2′-Deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodocytosine] (FIAC)(I) [69123-90-6], [1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodouracil] (FIAU)(II) [69123-98-4], and [1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-methyluracil] (FMAU)(III) [69256-17-3] were evaluated for their efficacies in the treatment of genital infections with herpes simplex virus type 2 in guinea pigs. I.p. administration of these drugs in daily doses of 100 mg/kg of body weight initiated 24 h after virus inoculation and repeated 2 successive days thereafter inhibited development of genital lesions and reduced shedding of virus without evoking untoward reactions. In a comparative study with this 3-day dosage schedule, the efficacy of daily doses of 50 mg of FMAU per kg was greater than that of the same doses of FIAC and FIAU, in that order; all these were more effective than daily doses of 50, 100, or 200 mg of acyclovir or of 500 mg of phosphonoformic acid per kg. These differences in efficacy were enhanced when treatment was delayed for 2 to 3 days after inoculation. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Recommanded Product: 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidine also found in many synthetic compounds such as barbiturates and the HIV drug, zidovudine. We all know its importance to life – pyrimidine and purine bases are included in the structure of DNA and RNA.Recommanded Product: 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Differential activity of potential antiviral nucleoside analogs on herpes simplex virus-induced and human cellular thymidine kinases was written by Cheng, Y. C.; Dutschman, G.; Fox, J. J.; Watanabe, K. A.; Machida, H.. And the article was included in Antimicrobial Agents and Chemotherapy on September 30,1981.Recommanded Product: 69256-17-3 The following contents are mentioned in the article:

The rates of phosphorylation of the potential antiviral nucleoside analogs I (R = I, Me, CH:CHBr; R1 = H, F, OH) and II (R = I, Me) by purified thymidine kinase [9002-06-6] from both human and herpes simplex virus sources were studied. Most of the analogs were phosphorylated by both human and viral kinases. The analogs were competitive inhibitors of thymidine phosphorylation by the kinases; on the assumption that inhibition constants (Ki) reflect binding affinity, Ki values of the analogs were determined In general, the analogs have a greater affinity for the viral kinases than for the human kinases. The amount of the analogs phosphorylated to the monophosphate form, which is presumably necessary for cytotoxic activity, was dependent on both the phosphorylation rates and binding affinities. All of the analogs act as preferential substrates for the viral kinases at low concentrations, which may be one of the main reasons for their selective antiviral action. The structure-activity relations of the analogs are discussed. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Recommanded Product: 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Heterocyclic compounds bearing the pyrimidine core are of tremendous interest as they constitute an important class of natural and synthetic compounds exhibiting diverse useful biological activities that hold attractive potential for clinical translation as therapeutic agents in alleviation of a myriad of diseases. Drugs having the pyrimidine motif have manifested to exhibit gratifying biological activity like anticancer, antiviral, anti-inflammatory, antibacterial, and antihypertensive activities.Recommanded Product: 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Nucleotide sugar pucker preference mitigates excision by HIV-1 RT was written by Yamada, Ken; Wahba, Alexander S.; Bernatchez, Jean A.; Ilina, Tatiana; Martinez-Montero, Saul; Habibian, Maryam; Deleavey, Glen F.; Gotte, Matthias; Parniak, Michael A.; Damha, Masad J.. And the article was included in ACS Chemical Biology on September 18,2015.Formula: C10H13FN2O5 The following contents are mentioned in the article:

A series of DNA primers containing nucleotides with various sugar pucker conformations at the 3′-terminus were chem. synthesized by solid-phase synthesis. The ability of wild-type (WT) HIV-1 reverse transcriptase (RT) and AZT-resistant (AZTr) RT to excise the 3′-terminal nucleotide was assessed. Nucleosides with a preference for the North conformation were more refractory to excision by both WT-RT and AZTr-RT. We found that DNA primers that contain North puckered-nucleotides at the 3′-terminus can also affect the translocation status of the RT/template/primer complex, which provides an underlying mechanism to avoid being excised. Together, these results point to a correlation between the sugar conformation of the 3′-terminal nucleotide, the precise position of HIV-1 RT on its nucleic acid substrate, and, in turn, its catalytic function. Nucleotide sugar conformation is therefore an important parameter in defining the susceptibility to RT-catalyzed phosphorolytic excision. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Formula: C10H13FN2O5).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Heterocyclic compounds bearing the pyrimidine core are of tremendous interest as they constitute an important class of natural and synthetic compounds exhibiting diverse useful biological activities that hold attractive potential for clinical translation as therapeutic agents in alleviation of a myriad of diseases. Drugs having the pyrimidine motif have manifested to exhibit gratifying biological activity like anticancer, antiviral, anti-inflammatory, antibacterial, and antihypertensive activities.Formula: C10H13FN2O5

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3